Abstract | PURPOSE: DESIGN: Retrospective observational cases series. PARTICIPANTS: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. METHODS: Physician survey, retrospective database review, and literature search. MAIN OUTCOME MEASURES: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). RESULTS: CONCLUSIONS:
|
Authors | Dan S Gombos, John Hungerford, David H Abramson, Judith Kingston, Guillermo Chantada, Ira J Dunkel, Celia B G Antoneli, Mark Greenwald, Barret G Haik, Carlos A Leal, Aurora Medina-Sanson, Amy C Schefler, Gavivann Veerakul, Regina Wieland, Norbert Bornfeld, Mathew W Wilson, Christopher Bing On Yu |
Journal | Ophthalmology
(Ophthalmology)
Vol. 114
Issue 7
Pg. 1378-83
(Jul 2007)
ISSN: 1549-4713 [Electronic] United States |
PMID | 17613328
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Podophyllotoxin
|
Topics |
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Child, Preschool
- Cohort Studies
- Databases, Factual
- Enzyme Inhibitors
(adverse effects, therapeutic use)
- Female
- Humans
- Infant
- Infant, Newborn
- Leukemia, Myeloid, Acute
(chemically induced)
- Male
- Neoplasms, Second Primary
(chemically induced)
- Podophyllotoxin
(adverse effects, therapeutic use)
- Retinal Neoplasms
(drug therapy)
- Retinoblastoma
(drug therapy)
- Retrospective Studies
- Time Factors
- Topoisomerase II Inhibitors
|